Bayer 경영진

경영진 기준 점검 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

핵심 정보

Bill Anderson

최고경영자

€9.2m

총 보수

CEO 급여 비율	24.36%
CEO 재임 기간	3yrs
CEO 지분 보유율	n/a
경영진 평균 재임 기간	3yrs
이사회 평균 재임 기간	7.2yrs

최근 경영진 업데이트

Recent updates

CEO 보수 분석

Bill Anderson의 보수는 Bayer의 수익에 비해 어떻게 변했나요?
날짜	총 보수	급여	회사 수익
Dec 31 2025	€9m	€2m	-€4b
Sep 30 2025	n/a	n/a	-€198m
Jun 30 2025	n/a	n/a	-€3b
Mar 31 2025	n/a	n/a	-€3b
Dec 31 2024	€9m	€2m	-€3b
Sep 30 2024	n/a	n/a	-€880m
Jun 30 2024	n/a	n/a	-€1b
Mar 31 2024	n/a	n/a	-€3b
Dec 31 2023	€12m	€2m	-€3b

보상 대 시장: Bill의 총 보수(USD10.84M)는 US 시장에서 비슷한 규모 기업의 평균(USD14.57M) 수준입니다.

보상과 수익: Bill의 보상은 회사가 적자임에도 증가했습니다.

CEO

Bill Anderson (59 yo)

3yrs

재임 기간

€9,236,000

보수

Mr. William N. Anderson, also known as Bill, is Member of Management Board of Bayer Aktiengesellschaft from April 1, 2023 and also serves as its Chairman of the Management Board and Chief Executive Officer...

리더십 팀

이름	직위	재임 기간	보수	지분
William Anderson	Chairman of the Management Board & CEO	3yrs	€9.24m	데이터 없음
Wolfgang Nickl	CFO & Member of Management Board	8yrs	€3.82m	데이터 없음
Stefan Oelrich	Head of the Pharmaceuticals Division & Member of the Board of Management	7.4yrs	€3.79m	데이터 없음
Heike Prinz	Chief Talent Officer	2.6yrs	€3.97m	데이터 없음
Rodrigo Santos	Member of Management Board & President of the Crop Science Division	4.3yrs	€3.77m	데이터 없음
Julio Triana	Member of Management Board & President of Consumer Health Division	2yrs	€3.58m	데이터 없음
Judith Hartmann	Member of Management Board	less than a year	데이터 없음	데이터 없음
Alex Buschermohle	Chief Information Officer	less than a year	데이터 없음	데이터 없음
Jost Reinhard	Senior VP & Head of Investor Relations	2.5yrs	데이터 없음	데이터 없음
Bill Dodero	General Counsel and Senior VP of Law Patents & Compliance	3.3yrs	데이터 없음	데이터 없음
Michael Preuss	Head of Communications	9.9yrs	데이터 없음	데이터 없음
Bernd-Peter Bier	Head of Group Finance	no data	데이터 없음	데이터 없음

3.0yrs

평균 재임 기간

57yo

평균 나이

경험이 풍부한 관리: BAYR.Y의 경영진은 경험이 있음으로 간주됩니다(평균 재임 3 년).

이사회 구성원

이름	직위	재임 기간	보수	지분
Paul M. Achleitner	Member of Supervisory Board	24yrs	€233.00k	데이터 없음
Ertharin Cousin	Independent Member of the Supervisory Board	6.5yrs	€240.00k	데이터 없음
Alberto Weisser	Independent Supervisory Board Member	5yrs	€223.00k	데이터 없음
Colleen Goggins	Independent Member of Supervisory Board	9yrs	€233.00k	데이터 없음
Lori Schechter	Independent Supervisory Board Member	2yrs	€304.00k	데이터 없음
Horst Baier	Independent Member of Supervisory Board	6yrs	€336.00k	데이터 없음
Heike Hausfeld	Vice Chairwoman of Supervisory Board	9yrs	€350.00k	데이터 없음
André van Broich	Member of Supervisory Board	14yrs	€279.00k	데이터 없음
Frank Löllgen	Member of Supervisory Board	10.4yrs	€268.00k	데이터 없음
Norbert Winkeljohann	Independent Chairman of Supervisory Board	7.9yrs	€518.00k	데이터 없음
Andrea Sacher	Member of Supervisory Board	5.6yrs	€244.00k	데이터 없음
Michael Westmeier	Employee Representative Member of the Supervisory Board	4yrs	€241.00k	데이터 없음

7.2yrs

평균 재임 기간

66yo

평균 나이

경험이 풍부한 이사회: BAYR.Y의 이사회는 경험이 있음으로 간주됩니다(평균 재임 7.2 년).

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/04/30 10:34
종가	2026/04/30 00:00
수익	2025/12/31
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Bayer Aktiengesellschaft는 40명의 분석가가 다루고 있습니다. 이 중 18명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Rafael Bonardell Trianes	Banco de Sabadell. S.A.
Emily Field	Barclays
Charles Pitman	Barclays

Bayer 경영진

경영진 기준 점검 3/4

핵심 정보

최근 경영진 업데이트

Bayer AG Announces Appointment of Nelson Ambrogio as President of U.S. Pharmaceuticals, Effective May 1, 2026

Bayer Aktiengesellschaft, Annual General Meeting, Apr 24, 2026

Bayer AG Announces Chief Financial Officer Changes

Bayer Announces Executive Changes for North America

Bayer Announces Changes to CFO for Crop Science Division, Effective July 1, 2025

Bayer Announces Management Changes, Effective April 15, 2025

Recent updates

Bayer AG Announces Appointment of Nelson Ambrogio as President of U.S. Pharmaceuticals, Effective May 1, 2026

Bayer Announces Kerendia Meets Primary Endpoint In Investigational Phase III Find-Ckd Study In Patients With Non-Diabetic Chronic Kidney Disease

Bayer Aktiengesellschaft to Report Q4, 2026 Results on Feb 24, 2027

Bayer Aktiengesellschaft to Report Q3, 2026 Results on Nov 03, 2026

Missouri Court Grants Preliminary Approval of Roundup Class Settlement to Resolve Current and Future Claims

Bayer Aktiengesellschaft, Annual General Meeting, Apr 24, 2026

Bayer Reports Results for the Investigational Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer

Bayer Announces XOFIGO (Radium-223 Dichloride) Plus Enzalutamide Demonstrates Significant Overall Survival Benefit In PEACE-3 Trial In Patients With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases

Monsanto Announces Roundup™ Class Settlement Agreement to Resolve Current and Future Claims

Bayer's Asundexian Demonstrated A Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleeding Versus Placebo

Bayer to Present Results from Phase III Oceanic-Stroke Study of Asundexian in Secondary Stroke Prevention

Askbio Inc. Announces Fda Acceptance of Investigational New Drug (Ind) Application for Ab-1009 Gene Therapy for Treatment of Late-Onset Pompe Disease

Bayer Starts Phase IIa Study for Treatment of Patients with Alport Syndrome

Bayer Starts New Phase III Study with Mirena®? for the Treatment of Nonatypical Endometrial Hyperplasia

Bayer Announces Positive Topline Results from the Global Phase III Study Oceanic-Stroke, with Its Investigational, Once Daily, Oral FXIa Inhibitor asundexian

U.S. FDA Approves HYRNUO®? (sevabertinib) for Previously Treated Patients with HER2-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Bayer Aktiengesellschaft to Report Q2, 2026 Results on Aug 04, 2026

Bayer AG Announces Chief Financial Officer Changes

Bayer Announces New Phase III Investigational Data from the Pivotal Fine-One Trial

Bayer Announces U.S. Food and Drug Administration Approval for Moderate to Severe Hot Flashes Due to Menopause

Hesperos and Bayer Consumer Health Develop First Human-On-A-Chip Model of Stress-Induced Cognitive Dysfunction

Bayer First Company to Advance Cell Therapy as Well as Gene Therapy Against Parkinson's Disease

Bayer®? Aspirin Introduces Aspirina to the U.S. Pain Market

Bayer Aktiengesellschaft to Report Q1, 2026 Results on May 12, 2026

Bayer Aktiengesellschaft to Report Q3, 2025 Results on Nov 12, 2025

Bayer Ag and BlueRock Therapeutics LP Announces First Patient Receives Investigational Therapy in Phase 1/2a Clinical Trial of OpCT-001 for the Treatment of Primary Photoreceptor Diseases

Bayer Announces Executive Changes for North America

Bayer Files for Approval of Gadoquatrane to the US Food and Drug Administration

U.S. FDA Approves Third Indication of Darolutamide for Patients with Advanced Prostate Cancer

Vividion Therapeutics, Inc. and Bayer Further Strengthen Oncology Development Pipeline with Clinical-Stage WRN Inhibitor

Elinzanetant Significantly Reduces Frequency of Moderate to Severe Vasomotor Symptoms Associated with Endocrine Therapy for Breast Cancer in Phase III Oasis-4 Study as Per Bayer

Bayer's XOFIGO (Radium-223 Dectloride) Combination Data Showcases Clinical Benefits in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases

Bayer Highlights New Data from Oncology and Women’S Health Portfolios At 2025 Asco Annual Meeting

Bayer Initiates Phase I Study Targeting GPC3 with Actinium-225 Radiopharmaceutical in Patients with Advanced Hepatocellular Carcinoma

Bayer Announces Changes to CFO for Crop Science Division, Effective July 1, 2025

Bayer to Unveil Latest NUBEQA®? (Darolutamide) Data and Prostate Cancer Research at American Urological Association (AUA) 2025 Annual Meeting

Bayer Receives Full FDA Approval For VITRAKVI®? As First-In-Class TRK Inhibitor

Elliott Reportedly Gauge Investor Interest in Bayer's Consumer Health Business

Bayer Announces Management Changes, Effective April 15, 2025

Bayer Announces U.S. FDA Accepts Supplemental New Drug Application Under Priority Review for New Indication for KERENDIA®? (Finerenone) in Patients with Heart Failure with Left Ventricular Ejection Fraction of 40%

Bayer Introduces Vyconic Soybeans at Commodity Classic 2025

Bayer Submits Supplemental New Drug Application to U.S. FDA Seeking New Indication for KERENDIA® (finerenone)

Bayer Announces Positive Topline Results of Phase Iii Study Oasis 4 Investigating Elinzanetant

Bayer Submits Application in China for Third Indication of Darolutamide

Bayer Aktiengesellschaft to Report Q2, 2025 Results on Aug 06, 2025

Bayer to Present New Prespecified Subgroup Analyses from Investigational Phase III FINEARTS-HF Trial in Patients with Heart Failure with LVEF =40% at AHA 2024

Bayer and Liveo Research Launches Blister Packaging with Improved Environmental Footprint

Bayer Submits Application for Third Indication of Darolutamide in the EU

U.S. Food and Drug Administration Accepts New Drug Application for Bayer's Elinzanetant

Bayer Ag and BlueRock Therapeutics LP Announces Positive 24-Month Data from exPDite

Bayer Submits Application to U.S. FDA for Third Indication of darolutamide

Bayer to Unveil New Data from its Phase III OASIS 3 Long-Term Study of Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause

Bayer Announces Late-Breaking KERENDIA® (finerenone) Investigational Data Presented

Bayer to Present Phase III Kerendia (Finerenone) Data

Bayer Announces Primary Endpoint Achieved in Phase III FINEARTS-HF Cardiovascular Outcomes Study Investigating KERENDIA in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Bayer Submits New Drug Application to U.S. FDA for Elinzanetant for the Treatment of Moderate to Severe Vasomotor Symptoms Associated With Menopause

Bayer Presents Latest Data from Oncology Portfolio at 2024 ASCO Annual Meeting

Bayer Starts Phase I Study with Novel Targeted Radionuclide Therapy 225Ac-Psma-Trillium in Advanced Metastatic Prostate Cancer

Bayer to Unveil Late-Breaking Data from Phase Iii Oasis 1 and 2 for Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause

Bayer AG and Asklepios BioPharmaceutical, Inc Presents Results from the 18-Month Phase Ib Clinical Trial for AB-1005

Bayer Appoints Sue Ann Pentecost as Head of U.S. Pharmaceutical Communications

Bayer Announces Positive Topline Results from Phase III Long-Term Study Oasis 3 Support Submits for Marketing Authorization for Bayer's Elinzanetant

Bayer Aktiengesellschaft, Annual General Meeting, Apr 25, 2025

Bayer Announces Start of Phase II Clinical Trial with BAY3018250

Bayer Aktiengesellschaft to Report Q1, 2024 Results on May 14, 2024

Bayer Aktiengesellschaft to Report Q4, 2023 Results on Mar 05, 2024

Bayer Announces Key Leadership Changes for its Crop Science Division

Bayer Starts Phase II Study Nirvana to Evaluate Elinzanetant in Women with Sleep Disruptments Associated with Menopause

Williams Hart & Boundas Wins Against Bayer